(110 days)
No
The summary describes new sequences, coils, and workflow enhancements for existing MR systems. There is no mention of AI or ML in the intended use, device description, or performance studies.
No
The device is described as a "magnetic resonance diagnostic device" used to produce images and spectra that "assist in diagnosis," not for treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that "The MAGNETOM systems are indicated for use as magnetic resonance diagnostic devices (MRDD)..." and that the information derived from the images and spectra "may assist in diagnosis."
No
The device description explicitly states that the software is being made available for existing MAGNETOM MR Systems and mentions the availability of two new coils. This indicates the device is a system that includes both hardware (the MR systems and coils) and software, not a software-only device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the MAGNETOM systems are "magnetic resonance diagnostic devices (MRDD)" that produce images and spectra of the internal structure and/or function of the body. These images and parameters are then "interpreted by a trained physician" to "assist in diagnosis." This describes an imaging system used for in-vivo (within the living body) diagnosis, not in-vitro (outside the living body) testing of biological samples.
- Device Description: The description details software and hardware components for an MRI system, which is an imaging modality. It discusses sequences, coils, and workflows for acquiring images of the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), reagents, or any of the typical components or processes associated with in-vitro diagnostics.
Therefore, the device described is an MRI system used for medical imaging, which falls under the category of diagnostic imaging devices, not in-vitro diagnostic devices.
N/A
Intended Use / Indications for Use
The MAGNETOM systems are indicated for use as magnetic resonance diagnostic devices (MRDD) that produce transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and or spectra, and that display the internal structure and/or function of the head, body or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the inages and/or spectra when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems described above may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
Product codes (comma separated list FDA assigned to the subject device)
LNH, LNI, MOS
Device Description
The subject device, synqo MR E11B system software, is being made available for the following MAGNETOM MR Systems:
- MAGNETOM Aera (24-channel configuration), .
- MAGNETOM Avanto™ ●
- MAGNETOM Skyra™, ●
- . MAGNETOM Prisma and
- . MAGNETOM Prisma™
Two new coils, Body 30/60 and Body 6 long, will be available for the subject device systems. The feature FREEZEit will be extended to other body regions. In addition to the abdomen region, FREEZEit will be extended to other regions such as the head, head and neck, pelvis, and chest region. . The syngo MR E11B SW also includes new sequences as well as minor modifications of already existing features. A high level summary of the new sequences can be viewed below:
DSI
With software version syngo MR E11B Siemens offers DSI for MAGNETOM Prisma, Prismall and Skyra" systems. The DSI option allows diffusion-weighted images to be acquired according to a DSI-compatible q-space sampling scheme.
DSI is based on sampling the "q-space", where "q-space" is defined in analogy to the "kspace" by the moment of the diffusion encoding gradients G: g = y/2π J G(t) dt.
While the Fourier transform of k-space data generates the image content, a Fourier transform of q-space data allows calculating a probability density function. This data provides information about the probability of a particle moving to a certain position in space within a certain time interval by diffusive motion.
The DSI Application is only available for MAGNETOM Prisma/Prisma™ and Skyraf" Systems.
QISS evaluation
QISS (Quiescent-Interval Single-Shot) MR Angiography is a technique for non-contrastenhanced MR Angiography (non-CEMRA) that is particularly suited for examinations of patients with PAD. Since patients with PAD may also suffer from additional impairments such as renal dysfunction, the administration of contrast agent may often be unadvisable in this patient group. Siemens provides a manageable and optimized QISS workflow for imaging peripheral arteries, which can be easily adapted by the customer based on the patient's needs.
RT Dot Engine
A new "Dot Engine" is provided to ease MRI acquisitions in Radiation Therapy.
RT Dot Engine is a new Dot Engine for aiding in Radiation Therapy planning. The RT Dot Engine does not provide new functionality, but collects and displays existing system information for the user. The RT Dot Engine comprises existing protocols, enhanced with the RT Planning Dot Add-in and the "MPR Planning" interaction step. The RT (Radiation Therapy) Dot Engine is used to ease MRI acquisitions of the head and the head/neck region with stereotactic frames or mask-based fixation techniques. RT Dot Engine is a workflow solution for acquiring MR images intended to aid in Radiation Therapy Planning. RT Dot engine helps streamline acquisition of MR images to be used along with any RT planning software that uses MR images in addition to CT images.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance
Anatomical Site
head, body or extremities.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical Tests:
- The coils were tested for SNR, image uniformity, and heating.
- Dedicated phantom testing was conducted on particular new sequences. ●
- Acoustic noise measurements were performed for quiet sequences
- . lmage quality assessments of all new/modified sequences and algorithms, were completed. In some cases a comparison of the image quality was made between the new/modified features and the predicate features.
The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
Clinical Tests:
No clinical tests were conducted to support the subject device and the substantial equivalence argument; however, clinical images were provided to support the new coils as well as the new software features of the subject device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of a caduceus, which is a symbol often associated with healthcare. The caduceus in the logo is composed of three intertwined figures.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 29, 2015
Siemens Medical Solutions USA, Inc. % Cordell Fields, Esq. Regulatory Affairs Specialist 51 Valley Stream Parkway MALVERN PA 19355
Re: K151579
Trade/Device Name: MAGNETOM Aera (24-channel). MAGNETOM Ayantofit. MAGNETOM Skyrafit, MAGNETOM Prisma/ Prismafit Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: II Product Code: LNH, LNI, MOS Dated: August 28, 2015 Received: August 31, 2015
Dear Mr. Fields:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Robert Oolo
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows the word "SIEMENS" in a teal, sans-serif font. The letters are large and bold, taking up most of the frame. The background is plain white, which makes the text stand out. The logo is simple and modern.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K151579
Device Name
MAGNETOM Aera (24-channel), MAGNETOM Avantofit, MAGNETOM Skyrafit, MAGNETOM Prisma Prismafit
Indications for Use (Describe)
The MAGNETOM systems are indicated for use as magnetic resonance diagnostic devices (MRDD) that produce transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and or spectra, and that display the internal structure and/or function of the head, body or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and the physical parameters derived from the inages and/or spectra when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems described above may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/14)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EEF
Siemens 510(k) Premarket Notification
June 9, 2015
Syngo MR E11B for MAGNETOM Aera (24) (1.5T), MAGNETOM Avanto fit (1.5T), MAGNETOM Skyra fit (3T) and MAGNETOM Prisma/Prisma fit (3T)
3
Section 5 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92.
I. General Information
| Establishment | Siemens Medical Solutions USA. Inc.
65 Valley Stream Parkway
Mail Code 65-1A
Malvern, PA 19355, USA |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Registration Number | 2240869 |
| Date Prepared | June 9, 2015 |
| Manufacturer | Siemens AG
Henkestrasse 127
D-91052 Erlangen, Germany
Registration Number: 002808157 |
| | SIEMENS SHENZHEN MAGNETIC RESONANCE LTD.
Siemens MRI Center
Hi-Tech Industrial park (middle)
Gaoxin C. Ave., 2nd
Shenzhen 518057, P.R. CHINA
Registration Number: 3004754211 |
4
Section 5: 510(k) Summary
- Contact Person Mr. Cordell L. Fields, Esq. Regulatory Affairs Specialist Siemens Healthcare Siemens Medical Solutions USA, Inc. Customer Solutions Group 51 Valley Stream Parkway Malvern, PA 19355, USA Phone: (610) 448-8518 Fax: (610) 448-1787
- Syngo MR E11 for MAGNETOM Aera (24) (1.5T), MAGNETOM Device Name Avantoff (1.5T), MAGNETOM Skyra™ (3T) and MAGNETOM Prisma/Prismatit (3T)
- Trade Names:
MAGNETOM Aera MAGNETOM Skyra™ MAGNETOM Avanto™ MAGNETOM Prisma MAGNETOM Prisma™
| Classification Name: | Magnetic Resonance Diagnostic Device (MRDD |
|---|---|
| Classification Panel: | Radiology |
| CFR Code: | 21 CFR § 892.1000 |
| Classification: | Class II |
| Product Code: | Primary: LNH, Secondary: LNI, MOS |
Siemens 510(k) Premarket Notification
5
II. Safety and Effectiveness Information Supporting Substantial Equivalence
Intended Use
The MAGNETOM systems [MAGNETOM Aera, MAGNETOM Skyra", MAGNETOM Avanto", MAGNETOM Prisma and MAGNETOM Prisma""] are indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities.
Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.
The MAGNETOM systems may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-Safe biopsy needles.
Device Description
The subject device, synqo MR E11B system software, is being made available for the following MAGNETOM MR Systems:
- MAGNETOM Aera (24-channel configuration), .
- MAGNETOM Avanto™ ●
- MAGNETOM Skyra™, ●
- . MAGNETOM Prisma and
- . MAGNETOM Prisma™
Two new coils, Body 30/60 and Body 6 long, will be available for the subject device systems. The feature FREEZEit will be extended to other body regions. In addition to the abdomen region, FREEZEit will be extended to other regions such as the head, head and neck, pelvis, and chest region. . The syngo MR E11B SW also includes new sequences as well as minor modifications of already existing features. A high level summary of the new sequences can be viewed below:
DSI
With software version syngo MR E11B Siemens offers DSI for MAGNETOM Prisma, Prismall and Skyra" systems. The DSI option allows diffusion-weighted images to be acquired according to a DSI-compatible q-space sampling scheme.
Siemens 510(k) Premarket Notification
Syngo MR E11B for MAGNETOM Aera (24) (1.5T), MAGNETOM Avanto fit (1.5T), MAGNETOM Skyra fit (3T) and MAGNETOM Prisma/Prisma fit (3T)
6
DSI is based on sampling the "q-space", where "q-space" is defined in analogy to the "kspace" by the moment of the diffusion encoding gradients G: g = y/2π J G(t) dt.
While the Fourier transform of k-space data generates the image content, a Fourier transform of q-space data allows calculating a probability density function. This data provides information about the probability of a particle moving to a certain position in space within a certain time interval by diffusive motion.
The DSI Application is only available for MAGNETOM Prisma/Prisma™ and Skyraf" Systems.
QISS evaluation
QISS (Quiescent-Interval Single-Shot) MR Angiography is a technique for non-contrastenhanced MR Angiography (non-CEMRA) that is particularly suited for examinations of patients with PAD. Since patients with PAD may also suffer from additional impairments such as renal dysfunction, the administration of contrast agent may often be unadvisable in this patient group. Siemens provides a manageable and optimized QISS workflow for imaging peripheral arteries, which can be easily adapted by the customer based on the patient's needs.
A new "Dot Engine" is provided to ease MRI acquisitions in Radiation Therapy.
RT Dot Engine
RT Dot Engine is a new Dot Engine for aiding in Radiation Therapy planning. The RT Dot Engine does not provide new functionality, but collects and displays existing system information for the user. The RT Dot Engine comprises existing protocols, enhanced with the RT Planning Dot Add-in and the "MPR Planning" interaction step. The RT (Radiation Therapy) Dot Engine is used to ease MRI acquisitions of the head and the head/neck region with stereotactic frames or mask-based fixation techniques. RT Dot Engine is a workflow solution for acquiring MR images intended to aid in Radiation Therapy Planning. RT Dot engine helps streamline acquisition of MR images to be used along with any RT planning software that uses MR images in addition to CT images.
Technological Characteristics
SW syngo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto®, MAGNETOM Skyra™, MAGNETOM Prisma and MAGNETOM Prisma™ has the same technological characteristics as the predicate device systems (K141977; cleared November 19, 2014).
Siemens 510(k) Premarket Notification
7
SW syngo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto®, MAGNETOM Skyra™, MAGNETOM Prisma and MAGNETOM Prisma™ is substantially equivalent with regard to acquiring MR images steps/features.
The syngo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avantoff, MAGNETOM Skyra™, MAGNETOM Prisma and MAGNETOM Prismat" is substantially equivalent with regard to operational environment, programming language, operating system and performance.
synqo MR E11 for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto™, MAGNETOM Skyra™, MAGNETOM Prisma and MAGNETOM Prisma"", conform to the standard for software medical devices (IEC 62304:2006) and IEC as well as NEMA standards.
While syngo MR E11B offers additional capabilities with respect to the predicate device systems, the syngo MR E11B software on the subject device MR Systems has the same technological characteristics as the predicate device systems (K141977; cleared November 19, 2014).
Nonclinical Tests
The following performance testing was conducted on syngo MR E11B SW subject device:
- The coils were tested for SNR, image uniformity, and heating.
- Dedicated phantom testing was conducted on particular new sequences. ●
- Acoustic noise measurements were performed for quiet sequences
- . lmage quality assessments of all new/modified sequences and algorithms, were completed. In some cases a comparison of the image quality was made between the new/modified features and the predicate features.
The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
Clinical Tests
No clinical tests were conducted to support the subject device and the substantial equivalence argument; however, clinical images were provided to support the new coils as well as the new software features of the subject device.
Safety and Effectiveness
Siemens 510(k) Premarket Notification
8
SIEMENS
The device labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the device.
Risk management is ensured via a risk analysis in compliance with ISO 14971:2007 to identify and provide mitigation to potential hazards in a risk analysis beginning early in the design phase and continuing throughout the development of the product. These risks are controlled via measures realized in software development. SW testing and product labeling. To minimize risks, Siemens adheres to recognized and established industry practices and standards, such as the IEC 60601-1 series, to minimize electrical and mechanical risk. Furthermore, the operators are healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.
The syngo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto", MAGNETOM Skyra", MAGNETOM Prisma and MAGNETOM Prisma" conform to the applicable FDA recognized and international IEC, ISO and NEMA standards with regards to performance and safety as recommended by the respective MR FDA Guidance Document.
Substantial Equivalence
synqo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto", MAGNETOM Skyra", MAGNETOM Prisma and MAGNETOM Prisma" includes all of the features of the predicate device, systems MAGNETOM Aera and MAGNETOM Skyra with syngo MR E11A.
Predicate Device Information
| Predicate Device Name | FDA Clearance
Number and Date | Product
code | Manufacturer |
|---------------------------------------------------------|---------------------------------------|-----------------|-------------------------------|
| syngo MR E11A for the
MAGNETOM systems
Aera/Skyra | K141977, cleared
November 19, 2014 | LNH
LNI,MOS | Siemens
Healthcare
GmbH |
Reference Device Information
| Reference Device Name | FDA Clearance
Number and
Date | Product
code | Manufacturer |
|-------------------------------------|--------------------------------------------|-----------------|-------------------------------|
| MAGNETOM Aera with syngo
MR D13E | K132951 cleared at
15 November,
2013 | Primary
LNH | Siemens
Healthcare
GmbH |
Siemens 510(k) Premarket Notification
June 9, 2015
Syngo MR E11B for MAGNETOM Aera (24) (1.5T), MAGNETOM Avanto fit (1.5T), MAGNETOM Skyra fit (3T) and MAGNETOM Prisma/Prisma fit (3T)
9
| Reference Device Name | FDA Clearance
Number and
Date | Product
code | Manufacturer |
|---------------------------------------------|--------------------------------------------|-----------------|-------------------------------|
| MAGNETOM Avantofit and
MAGNETOM Skyrafit | K130885 cleared at
17 May, 2013 | Primary
LNH | Siemens
Healthcare
GmbH |
| MAGNETOM Prisma and
MAGNETOM Prismafit | K132119 cleared at
22 November,
2013 | Primary
LNH | Siemens
Healthcare
GmbH |
Conclusion as to Substantial Equivalence
synqo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto®", MAGNETOM Skyra®, MAGNETOM Prisma and MAGNETOM Prisma™ has the same intended use and the same basic technological characteristics as the predicate device, systems MAGNETOM Aera and MAGNETOM Skyra with syngo MR E11A, with respect to the magnetic resonance features and functionalities.
MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto", MAGNETOM Skyra™, MAGNETOM Prisma and MAGNETOM Prisma™ with software syngo MR E11B will be used for acquiring MR images (transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra.)
The differences between the MR systems with the subject device software and the predicate device SW, including the aforementioned new software and hardware options, give the subject device the same capabilities as the predicate device systems. While there are some minor technical features that vary with respect to the predicate device MR Systems, the conclusions from the non-clinical data suggest that the features with different technological characteristics from the predicate device bear an equivalent safety and performance profile as that of the predicate and reference devices.
syngo MR E11B for MAGNETOM Aera (24-channel configuration), MAGNETOM Avanto fit, MAGNETOM Skyra fit, MAGNETOM Prisma and MAGNETOM Prisma" is similar to the functionalities of the predicate device, and does not introduce any new issues of safety or effectiveness.
Therefore, Siemens is of the opinion that syngo MR E11 for MAGNETOM Aera (24channel configuration), MAGNETOM Avanto(4, MAGNETOM Skyra(*, MAGNETOM Prisma and MAGNETOM Prisma™ does not raise new questions of safety or effectiveness and is substantially equivalent to the currently marketed device
Siemens 510(k) Premarket Notification
10
MAGNETOM Aera/ Skyra with software syngo MR E11A (K141977 cleared on November 19, 2014).